What are the latest figures on the choroidal neovascularization market’s size and projected CAGR?
The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the growing prevalence of sedentary lifestyle diseases, increasing prevalence of age-related macular degeneration, rising incidence of retinal illnesses, rising aged population, rising eye care costs, and expanding education and screening initiatives.
The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing patient awareness, growing adoption of optical coherence tomography angiography, growing demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Major trends in the forecast period include the emergence of intravitreal anti-vascular endothelial (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.
Get Your Free Sample of The Global Choroidal Neovascularization Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp
Which Market drivers have played a significant role in driving the choroidal neovascularization market?
The rising prevalence of age-related macular degeneration (AMD) is expected to propel the growth of the choroidal neovascularization (CNV) market going forward. Age-related macular degeneration (AMD) is an eye disease that gradually damages the macula, leading to central vision loss, primarily in older adults. The rising prevalence of age-related macular degeneration (AMD) is due to the aging population, increased life expectancy, lifestyle changes, genetic factors, and greater exposure to environmental risks. Choroidal neovascularization (CNV) supports age-related macular degeneration (AMD) patients by contributing to the development of wet AMD, where the growth of abnormal blood vessels beneath the retina leads to vision deterioration, requiring advanced treatments such as anti-VEGF therapy to manage choroidal neovascularization (CNV) and slow the progression of age-related macular degeneration (AMD), ultimately preserving central vision in affected individuals. For instance, in September 2022, according to the National Institutes of Health, a US-based government agency, by 2040, age-related macular degeneration (AMD) cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the increasing prevalence of age-related macular degeneration is driving the growth of the choroidal neovascularization market.
What are the key segments within the choroidal neovascularization market?
The choroidal neovascularization market covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report
Which key players are shaping the choroidal neovascularization market?
Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.
Which transformative trends will shape the choroidal neovascularization market landscape?
Major companies operating in the choroidal neovascularization market are focusing on developing innovative therapies, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment options that improve patient outcomes and treatment delivery. Photodynamic therapy (PDT) is a medical treatment that uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser approved by the Food and Drug Administration, a US-based federal agency. This therapy is approved for the use with Bausch + Lomb’s VISUDYNE therapy, designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.
How do regional factors impact the choroidal neovascularization market, and which region is the largest contributor?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Choroidal Neovascularization Market Report 2025 Offer?
The choroidal neovascularization market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
